Fresh Baked: An Overview of Newly FDA-Approved Drugs for Dermatological Usage
- PMID: 38371570
- PMCID: PMC10869024
- DOI: 10.4103/ijd.IJD_809_23
Fresh Baked: An Overview of Newly FDA-Approved Drugs for Dermatological Usage
Abstract
With our better understanding of the pathogenesis of various diseases, more and more drugs and biological products are being tried and tested every day. Roughly, around 40-50 novel drugs get approved by the Food and Drug Administration (FDA) for use in the general population, making it difficult for a physician to keep track of the constant changes in therapy. This article aimed to provide a compilation of all the FDA-approved new drugs for dermatological conditions and new dermatological indications of known drugs in the recent past, especially for dermatology residents and practising dermatologists. A comprehensive analysis, based on the list of new molecular entities approved by the FDA from 2020 to 2023, as well as a thorough English language literature search from 2020 to July 2023 across multiple databases (PubMed, MEDLINE, Springer Nature, Google Scholar and Cochrane) for various keywords (alone and in combination) such as "FDA approved" OR "recent advances in therapy" OR "recent drugs" OR "novel treatment" OR "dermatology," was performed. All data extracted were incorporated into the present compilation. A total of 33 drugs, including newly approved and newly approved indications of previously known drugs, were found. Relevant information about them has been discussed in a tabulated manner. This article provides an at a glance summarised profile of the newly FDA-approved drugs, as available in the existing literature. However, with the astonishing rate of new drugs hitting the market, more and more clinical trials are required to ensure the rational use of these agents.
Keywords: Autoimmune; FDA-approved; dermatology; drugs; genetic; infections; inflammatory; malignant; new; wound healing.
Copyright: © 2023 Indian Journal of Dermatology.
Conflict of interest statement
There are no conflicts of interest.
Figures
Similar articles
-
From the History of the Croatian Dermatovenereological Society - The Croatian Medical Association and an Overview of Important Information Regarding the Journal Acta Dermatovenerologica Croatica.Acta Dermatovenerol Croat. 2018 Dec;26(4):344-348. Acta Dermatovenerol Croat. 2018. PMID: 30665489
-
Insights into the FDA 2018 New Drug Approvals.Curr Drug Discov Technol. 2021;18(2):293-306. doi: 10.2174/1570163816666191202104315. Curr Drug Discov Technol. 2021. PMID: 31793428 Review.
-
Evaluation of Drug Trials in High-, Middle-, and Low-Income Countries and Local Commercial Availability of Newly Approved Drugs.JAMA Netw Open. 2021 May 3;4(5):e217075. doi: 10.1001/jamanetworkopen.2021.7075. JAMA Netw Open. 2021. PMID: 33950209 Free PMC article.
-
Synthesis and clinical application of new drugs approved by FDA in 2022.Mol Biomed. 2023 Sep 4;4(1):26. doi: 10.1186/s43556-023-00138-y. Mol Biomed. 2023. PMID: 37661221 Free PMC article. Review.
-
Drugs and other product choices.Dermatol Ther. 2009 May-Jun;22(3):216-24. doi: 10.1111/j.1529-8019.2009.01234.x. Dermatol Ther. 2009. PMID: 19453345 Review.
References
-
- New Drugs at FDA: CDER's New Molecular Entities and New Therapeutic Biological Products. Available online: https://www.fda.gov/drugs/development-approval-process-drugs/new-drugs-f... .
-
- WINLEVI® (Clascoterone) Cream, for Topical Use. [[Last accessed on 2023 Jul 20]]. Available from: https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/213433s000lbl.pdf .
-
- VTAMA® (Tapinarof) Cream, for Topical Use. [[Last accessed on 2023 Jul 20]]. Available from: https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/215272s000lbl.pdf .
LinkOut - more resources
Full Text Sources
Miscellaneous